All In Biotech

Drug Trial Radar · NCT06132893

A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects With Refractory Focal Onset Epilepsy

Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 390 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

390

Planned (sponsor's estimate)

Start

Mar 14, 2024

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Biohaven Therapeutics Ltd.Industry
Sponsor type
Industry
First posted
Nov 15, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.

Conditions

  • Focal Epilepsy

Interventions

  • BHV-7000Drug

    BHV-7000 25 mg. Participants will take blinded investigational product (IP) once daily

  • BHV-7000Drug

    BHV-7000 50 mg. Participants will take blinded investigational product (IP) once daily

  • PlaceboDrug

    Matching placebo taken once daily

  • BHV-7000Drug

    BHV-7000 75 mg. Participants willtake blinded investigational product(IP) once daily

  • PlaceboDrug

    Matching placebo taken once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part B: Change from Baseline in 28-day average seizure frequencyTime frame: Baseline, Week 8 to Week 20 of Part B
  2. Part A: Number of Participants With Deaths, Serious AEs (SAEs), AEs Leading to Study Drug Discontinuation, and moderate or severe AEsTime frame: Week 8 to Week 20 of Part A
  3. Part A: Number of Participants With Clinically Significant Laboratory AbnormalitiesTime frame: Week 8 to Week 20 of Part A

Locations

104 sites in 12 countries. Site status is shown where the registry gives one.

  • Barrow Neurological Institute

    Phoenix, Arizona

  • Center for Neurosciences

    Tucson, Arizona

  • Clinical Trials, Inc.

    Little Rock, Arkansas

  • University of California San Diego

    La Jolla, California

  • University of California, Los Angeles

    Los Angeles, California

  • Stanford Health Care

    Palo Alto, California

  • Profound Research LLC

    Pasadena, California

  • University of Colorado Anschultz Medical Campus

    Aurora, Colorado

  • Yale School of Medicine - Yale-New Haven Hospital

    New Haven, Connecticut

  • EZR Research LLC

    Boca Raton, Florida

  • Nova Clinical Research, LLC

    Bradenton, Florida

  • University of Florida (Jacksonville)

    Jacksonville, Florida

  • University of Miami

    Miami, Florida

  • Medsol Clinical Research Center

    Port Charlotte, Florida

  • Santos Research Center

    Tampa, Florida

  • Encore Medical Research of Weston LLC.

    Weston, Florida

  • Augusta University

    Augusta, Georgia

  • Hawaii Pacific Neuroscience

    Honolulu, Hawaii

  • Consultants in Epilepsy & Neurology, PLLC

    Boise, Idaho

  • Northwestern University

    Chicago, Illinois

  • Revive Research Institute, Inc.

    Elgin, Illinois

  • Bluegrass Epilepsy Research

    Lexington, Kentucky

  • MAESC

    Bethesda, Maryland

  • Javara

    Silver Spring, Maryland

  • Minnesota Epilepsy Group, P.A.

    Roseville, Minnesota

  • Washington University School of Medicine

    St Louis, Missouri

  • NEREG

    Hackensack, New Jersey

  • Inst of Neurology

    Livingston, New Jersey

  • Dent Neurosciences Research Center

    Amherst, New York

  • BCHP

    Hawthorne, New York

  • Northwell Health

    New York, New York

  • Stony Brook Medicine

    Stony Brook, New York

  • Five Towns Neuroscience Research

    Woodmere, New York

  • Wake Forest Baptist

    Winston-Salem, North Carolina

  • NeuroScience Research Center

    Canton, Ohio

  • University of Cincinnati

    Cincinnati, Ohio

  • OSU

    Columbus, Ohio

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

  • UPMC

    Pittsburgh, Pennsylvania

Showing 40 of 104 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.